Iron and cancer: Recent insights

Annals of the New York Academy of Sciences

Volumn 1368, Issue 1, 2016, Pages 149-161

  Manz, David H ^a,b   Blanchette, Nicole L ^a   Paul, Bibbin T ^a   Torti, Frank M ^c   Torti, Suzy V ^a  

^a Department of Molecular Biology and Biophysics ^*

^b UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cancer; Ferritinophagy; Ferroptosis; Iron

Indexed keywords

FERROPORTIN; HEPCIDIN; IRON; MICRORNA; CATION TRANSPORT PROTEIN; METAL TRANSPORTING PROTEIN 1; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER PROGNOSIS; EPIGENETICS; FERRITINOPHAGY; FERROPTOSIS; GENE CONTROL; HUMAN; IRON METABOLISM; IRON STORAGE; IRON TRANSPORT; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; TUMOR GROWTH; ANIMAL; IRON OVERLOAD; METABOLISM; NEOPLASMS;

ANIMALS; CATION TRANSPORT PROTEINS; HUMANS; IRON; IRON OVERLOAD; NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84959124605     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13008     Document Type: Article

References (120)

1. Ganz, T. & E. Nemeth . 2012. Hepcidin and iron homeostasis. Biochim. Biophys. Acta 1823: 1434-1443.
2. Wang, J. & K. Pantopoulos . 2011. Regulation of cellular iron metabolism. Biochem. J. 434: 365-381.
3. Fonseca-Nunes, A., P. Jakszyn & A. Agudo . 2014. Iron and cancer risk: a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol. Biomarkers Prev. 23: 12-31.
4. Torti, S.V. & F.M. Torti . 2013. Iron and cancer: more ore to be mined. Nat. Rev. Cancer 13: 342-355.
5. Torti, S.V. & F.M. Torti . 2011. Ironing out cancer. Cancer Res. 71: 1511-1514.
6. Bystrom, L.M. & S. Rivella . 2015. Cancer cells with irons in the fire. Free Radic. Biol. Med 79: 337-342.
7. Munoz, M., I. Villar & J.A. Garcia-Erce . 2009. An update on iron physiology. World J. Gastroenterol. 15: 4617-4626.
8. Silva, B. & P. Faustino . 2015. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim. Biophys. Acta 1852: 1347-1359.
9. McKie, A.T. et al. 2000. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Molecular Cell 5: 299-309.
10. Gulec, S., G.J. Anderson & J.F. Collins . 2014. Mechanistic and regulatory aspects of intestinal iron absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 307: G397-G409.
11. Drakesmith, H., E. Nemeth & T. Ganz . 2015. Ironing out Ferroportin. Cell Metab. 22: 777-787.
12. Rishi, G., D.F. Wallace & V.N. Subramaniam . 2015. Hepcidin: regulation of the master iron regulator. Biosci. Rep. 35: e00192.
13. Zhang, D.L., M.C. Ghosh & T.A. Rouault . 2014. The physiological functions of iron regulatory proteins in iron homeostasis: an update. Front. Pharmacol. 5: 124.
14. Anderson, C.P. et al. 2012. Mammalian iron metabolism and its control by iron regulatory proteins. Biochim. Biophys. Acta 1823: 1468-1483.
15. Daniels, T.R. et al. 2006. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121: 159-176.
16. Daniels, T. R. et al. 2006. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121: 144-158.
17. Habashy, H.O. et al. 2010. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res. Treat. 119: 283-293.
18. Jeong da, E. et al. 2015. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis. Oncotarget 6: 33046-33064.
19. Whitney, J.F. et al. 1995. Transferrin receptor expression in nonsmall cell lung cancer. Histopathologic and clinical correlates. Cancer 76: 20-25.
20. Pantopoulos, K. 2004. Iron metabolism and the IRE/IRP regulatory system: an update. Ann. N.Y. Acad. Sci. 1012: 1-13.
21. O'Donnell, K.A. et al. 2006. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol. Cell. Biol. 26: 2373-2386.
22. Schonberg, D.L. et al. 2015. Preferential iron trafficking characterizes glioblastoma stem-like cells. Cancer Cell 28: 441-455.
23. Weinstein, R.E., B.H. Bond & B.K. Silberberg . 1982. Tissue ferritin concentration in carcinoma of the breast. Cancer 50: 2406-2409.
24. Weinstein, R.E. et al. 1989. Tissue ferritin concentration and prognosis in carcinoma of the breast. Breast Cancer Res. Treat. 14: 349-353.
25. Marcus, D.M. & N. Zinberg . 1974. Isolation of ferritin from human mammary and pancreatic carcinomas by means of antibody immunoadsorbents. Arch. Biochem. Biophys. 162: 493-501.
26. Kew, M. C. et al. 1978. Serum and tumour ferritins in primary liver cancer. Gut 19: 294-299.
27. Eshhar, Z., S.E. Order & D.H. Katz . 1974. Ferritin, a Hodgkin's disease associated antigen. Proc. Natl. Acad. Sci. U.S.A. 71: 3956-3960.
28. Rossiello, R., M.V. Carriero & G.G. Giordano . 1984. Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J. Clin. Pathol. 37: 51-55.
29. Alkhateeb, A.A., B. Han & J.R. Connor . 2013. Ferritin stimulates breast cancer cells through an iron-independent mechanism and is localized within tumor-associated macrophages. Breast Cancer Res. Treat. 137: 733-744.
30. Ruddell, R.G. et al. 2009. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 49: 887-900.
31. Chen, Y. et al. 2015. Disordered signaling governing ferroportin transcription favors breast cancer growth. Cell Signal. 27: 168-176.
32. Pinnix, Z.K. et al. 2010. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci. Transl. Med. 2: 43ra56.
33. Tesfay, L. et al. 2015. Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer Res. 75: 2254-2263.
34. Zhang, S. et al. 2014. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell. Signal. 26: 2539-2550.
35. Guo, W. et al. 2015. An important role of the hepcidin-ferroportin signaling in affecting tumor growth and metastasis. Acta Biochim. Biophys. Sin. 47: 703-715.
36. Delaby, C. et al. 2008. Sequential regulation of ferroportin expression after erythrophagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. Biochem. J. 411: 123-131.
37. Taylor, M. et al. 2011. Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology 140: 2044-2055.
38. Harada, N. et al. 2011. Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages. Arch. Biochem. Biophys. 508: 101-109.
39. Lymboussaki, A. et al. 2003. The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. J. Hepatol. 39: 710-715.
40. Wu, X.N. et al. 2014. Roles of the hepcidin-ferroportin axis and iron in cancer. Eur. J. Cancer Prev. 23: 122-133.
41. Ward, D.G. et al. 2008. Increased hepcidin expression in colorectal carcinogenesis. World J. Gastroenterol. 14: 1339-1345.
42. Tanno, T. et al. 2011. Hepcidin, anaemia, and prostate cancer. BJU Int. 107: 678-679.
43. Lamy, P.J., A. Durigova & W. Jacot . 2014. Iron homeostasis and anemia markers in early breast cancer. Clin. Chim. Acta 434: 34-40.
44. Mei, S. et al. 2014. Hepcidin and GDF15 in anemia of multiple myeloma. Int. J. Hematol. 100: 266-273.
45. Tisi, M.C. et al. 2014. Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. Leuk. Lymphoma 55: 270-275.
46. Abd Elmonem, E. et al. 2009. Hepcidin mRNA level as a parameter of disease progression in chronic hepatitis C and hepatocellular carcinoma. J. Egypt Natl. Canc. Inst. 21: 333-342.
47. Maccio, A. et al. 2015. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica 100: 124-132.
48. Blanchette, N.L. et al. 2015. Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev. Hematol. DOI: 10.1586/17474086.2016.1124757.
49. Ganz, T. & E. Nemeth . 2011. Hepcidin and disorders of iron metabolism. Annu. Rev. Med. 62: 347-360.
50. Ganz, T. & E. Nemeth . 2015. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 15: 500-510.
51. Anastas, J.N. & R.T. Moon . 2013. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13: 11-26.
52. Yu, H. et al. 2014. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14: 736-746.
53. Wakefield, L.M. & C.S. Hill . 2013. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13: 328-341.
54. Goh, J.B. et al. 2015. Endofin, a novel BMP-SMAD regulator of the iron-regulatory hormone, hepcidin. Sci. Rep. 5: 13986.
55. Brookes, M.J. et al. 2008. A role for iron in Wnt signalling. Oncogene 27: 966-975.
56. Xiong, S. et al. 2003. Signaling role of intracellular iron in NF-kappaB activation. J. Biol. Chem. 278: 17646-17654.
57. Chua, A.C. et al. 2010. Iron: an emerging factor in colorectal carcinogenesis. World J. Gastroenterol. 16: 663-672.
58. Kamai, T. et al. 2009. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer 9: 270.
59. Yang, W.S. & B.R. Stockwell . 2008. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15: 234-245.
60. Dixon, S.J. et al. 2012. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149: 1060-1072.
61. Dolma, S. et al. 2003. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell 3: 285-296.
62. Linkermann, A. et al. 2014. Synchronized renal tubular cell death involves ferroptosis. Proc. Natl. Acad. Sci. U.S.A. 111: 16836-16841.
63. Yagoda, N. et al. 2007. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447: 864-868.
64. Yu, Y. et al. 2015. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. 2: e1054549-1-e1054549-7.
65. Lemberg, K.M. 2011. Ferroptosis: A Novel Form of Cancer Cell Death Induced by the Small Molecule Erastin. Columbia University. Academic Commons. http://hdl.handle.net/10022/AC:P:19207.
66. Dixon, S.J. & B.R. Stockwell . 2014. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10: 9-17.
67. Dix, T.A. & J. Aikens . 1993. Mechanisms and biological relevance of lipid peroxidation initiation. Chem. Res. Toxicol. 6: 2-18.
68. Gao, M. et al. 2015. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59: 298-308.
69. Kwon, M.Y. et al. 2015. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget 6: 24393-24403.
70. Sun, X. et al. 2016. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63: 173-184.
71. Sun, X. et al. 2015. HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene 34: 5617-5625.
72. Marzenell, P. et al. 2013. Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells. J. Med. Chem. 56: 6935-6944.
73. Hagen, H. et al. 2012. Aminoferrocene-based prodrugs activated by reactive oxygen species. J. Med. Chem. 55: 924-934.
74. Weinberg, F. et al. 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 107: 8788-8793.
75. Louandre, C. et al. 2015. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett. 356: 971-977.
76. Meister, A. 1995. Glutathione metabolism. Methods Enzymol. 251: 3-7.
77. Ishii, T., Y. Sugita & S. Bannai . 1987. Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J. Cell. Physiol. 133: 330-336.
78. Vousden, K.H. & C. Prives . 2009. Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
79. Jiang, L. et al. 2015. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520: 57-62.
80. Jiang, L. et al. 2015. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses. Cell Cycle 14: 2881-2885.
81. Hayano, M. et al. 2016. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. Cell Death Differ 23: 270-278.
82. Brigelius-Flohe, R. & M. Maiorino . 2013. Glutathione peroxidases. Biochim. Biophys. Acta 1830: 3289-3303.
83. Yang, W.S. et al. 2014. Regulation of ferroptotic cancer cell death by GPX4. Cell 156: 317-331.
84. Friedmann Angeli, J. P. et al. 2014. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16: 1180-1191.
85. Shaw, A.T. et al. 2011. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 108: 8773-8778.
86. Dixon, S.J. et al. 2014. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3: e02523.
87. Weiwer, M. et al. 2012. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg. Med. Chem. Lett. 22: 1822-1826.
88. Lachaier, E. et al. 2014. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 34: 6417-6422.
89. Ooko, E. et al. 2015. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 22: 1045-1054.
90. Eling, N. et al. 2015. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2: 517-532.
91. Skouta, R. et al. 2014. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136: 4551-4556.
92. Matsushita, M. et al. 2015. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J. Exp. Med. 212: 555-568.
93. Kenific, C.M. & J. Debnath . 2015. Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol. 25: 37-45.
94. Krishan, S. et al. 2015. Iron metabolism and autophagy: a poorly explored relationship that has important consequences for health and disease. Nagoya J. Med. Sci. 77: 1-6.
95. Dowdle, W.E. et al. 2014. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat. Cell Biol. 16: 1069-1079.
96. Mancias, J.D. et al. 2014. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509: 105-109.
97. Mancias, J.D. et al. 2015. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. eLife 4: e10308.
98. Zhang, C. & F. Zhang . 2015. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell 6: 88-100.
99. He, L. & G.J. Hannon . 2004. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5: 522-531.
100. Jansson, M.D. & A.H. Lund . 2012. MicroRNA and cancer. Mol. Oncol. 6: 590-610.
101. Sangokoya, C., J.F. Doss & J.T. Chi . 2013. Iron-responsive miR-485-3p regulates cellular iron homeostasis by targeting ferroportin. PLoS Genet. 9: e1003408.
102. Yoshioka, Y. et al. 2012. Micromanaging iron homeostasis: hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins. J. Biol. Chem. 287: 34110-34119.
103. Kindrat, I. et al. 2015. Abstract 920: mechanism of the transferrin receptor 1 dysregulation in hepatocarcinogenesis. Cancer Res. 75: 920.
104. Shpyleva, S.I. et al. 2011. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res. Treat. 126: 63-71.
105. Andolfo, I. et al. 2010. Regulation of divalent metal transporter 1 (DMT1) non-IRE isoform by the microRNA Let-7d in erythroid cells. Haematologica 95: 1244-1252.
106. Hou, W., Q. Tian, N.M. Steuerwald, et al. 2012. The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochim. Biophys. Acta 1819: 1113-1122.
107. Hamara, K., A. Bielecka-Kowalska, K. Przybylowska-Sygut, et al. 2013. Alterations in expression profile of iron-related genes in colorectal cancer. Mol. Biol. Rep. 40: 5573-5585.
108. Castoldi, M. et al. 2011. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J. Clin. Invest. 121:1386-1396.
109. Hou, W. et al. 2010. MicroRNA-196 pepresses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 51: 1494-1504.
110. Chan, S.Y. et al. 2009. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 10: 273-284.
111. Qiao A. et al. 2013. MicroRNA-210 decreases heme levels by targeting ferrochelatase in cardiomyocytes. J. Am. Heart Assoc. 2: e000121.
112. Liao Y. et al. 2010. miR-214 regulates lactoferrin expression and pro-apoptotic function in mammary epithelial cells. J. Nutr. 140: 1552-1556.
113. Schaar, D.G., D.J. Medina, D.F. Moore, et al. 2009. miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp. Hematol. 37: 245-255.
114. Sangokoya et al. 2013. Iron-responsive miR-485-3p regulates cellular iron homeostasis by targeting ferroportin. PLoS Genet. 9: e1003408.
115. Liao Y. & B. Lonnerdal . 2010. miR-584 mediates post-transcriptional expression of lactoferrin receptor in Caco-2 cells and in mouse small intestine during the perinatal period. Int. J. Biochem. Cell Biol. 42: 1363-1369
116. Lund, A.H. & M. van Lohuizen . 2004. Epigenetics and cancer. Genes Dev. 18: 2315-2335.
117. Jones, P.A. 2012. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13: 484-492.
118. Wang, R.H. et al. 2005. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2: 399-409.
119. De Souza, C. & B.P. Chatterji . 2015. HDAC inhibitors as novel anti-cancer therapeutics. Recent Pat. Anticancer Drug Discov. 10: 145-162.
120. Wang, W. et al. 2010. Ferritin H induction by histone deacetylase inhibitors. Biochem. Pharmacol. 80: 316-324.